The Push for New COVID-19 Vaccines Amid Safety Concerns and Low Case Rates

The FDA’s vaccine advisory committee unanimously recommended a monovalent JN.1-lineage COVID-19 vaccine for the 2024-2025 formula despite low COVID-19 hospitalization and death rates. Concerns were raised about vaccine safety, with bioscience researcher David Wiseman highlighting potential cancer risks linked to the vaccines. Critics, like Dr. Mary Tally Bowden, called for removing COVID-19 vaccines from the market due to adverse reactions. The committee did not address the 1.6 million injury reports in the VAERS system.

Editor’s Note: The urgency to push another COVID-19 vaccine appears to stem from a place of fear rather than necessity, especially when potential risks, such as cancer linked to the vaccines, are highlighted by experts. Ignoring the 1.6 million injury reports in the VAERS system further undermines the transparency and accountability the public deserves when it comes to decisions like this. Critics like Dr. Mary Tally Bowden are right to question the continued promotion of these vaccines when adverse reactions are evident.

Read Original Article